Needham & Company Starts Sagent Pharmaceuticals (SGNT) at Buy; New Kid On The Generic Block Should More Than Just Get By
Tweet Send to a Friend
Needham & Company initiates coverage on Sagent Pharmaceuticals (NASDAQ: SGNT) with a Buy. PT $28.
Needham analyst says, "Over the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Over the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
